Endonovo Therapeutics Files Patent for Treating Chemical and Radiation Injuries 
Using Next-Generation Biologics
 
Next-Generation Biologics Include Cell Therapies and Human
Biomolecules Produced by Electromagnetic Stimulation of Adult Stem
Cells
 
LOS ANGELES, CA -- (Marketwired) -- 08/10/16 --  Endonovo
Therapeutics, Inc. (OTCQB: ENDV), a developer of bioelectronic
devices and non-invasive Electroceuticals for the treatment of
inflammatory conditions in vital organs, announced today that it has
filed a patent titled, "Methods and Compositions for Treating
Chemical and Radiation Injuries." The patent filing covers the
production of biologics, including cell therapies and biomolecules
created using a proprietary bioreactor and their corresponding
administration as a therapeutic for treating chemical and radiation
injuries, including chemotherapy and radiation exposure.
 
This patent filing is a continuation-in-part of the patent described
in the announcement dated August 9, 2016.
 
Next-Generation Biologics, including growth factors and cell
therapies seek to overcome the shortcomings of current therapies,
including inconvenient dosing, immunogenicity and other side effects.
Visiongain predicts a market for next-generation biologics of $30
billion with five blockbuster biologics being developed by the year
2024.
 
Alan Collier, Endonovo's Chief Executive Officer, commented, "Now
that we have an issued patent covering our proprietary process, which
effectively trains cells to secrete therapeutic proteins, such as
G-CSF, GM-CSF, EPO and IL-2, we can begin pursuing several
indications using our Cytotronics platform."
 
"Many of the biomolecules that we can train cells to produce are used
to promote the growth of specific blood cells, including,
blood-forming stem cells, infection-fighting white blood cells and
oxygen carrying red blood cells. We believe that we can also expand
blood-forming stem cells to replace damaged or lost cells and train
and enhance them using our proprietary process to deliver a cocktail
of therapeutic proteins," said Mr. Collier. 
 
About Endonovo Therapeutics
 
Endonovo Therapeutics, Inc. is a leading developer of
bioelectronic-applications in cell therapies and non-invasive
Electroceuticals(TM). Endonovo's Immunotronics(TM) platform is
dedicated to treating patients with life-threatening inflammatory
conditions, such as acute liver injury and fulminant hepatic failure,
using proprietary non-invasive Electroceutical(TM) devices. The
Company's non-invasive platform is based on magnetically-induced
electrical field pathways that target inflammation and cell death.
 
The Company's Cytotronics(TM) platform harnesses the bulk electrical
properties of cells and tissues, namely magnetically-induced
electrical field pathways to expand and enhance the therapeutic
potential of cell therapies and produce next-generation biologics.
 
Safe Harbor Statement
 
This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
All statements, trends, analysis, and other information contained in
this press release including words such as "anticipate," "believe,"
"plan," "estimate," "expect," "intend," and other similar expressions
of opinion, constitute forward-looking statements. Any such
forward-looking statements involve risks and uncertainties that could
cause actual results to differ materially from any future results
described within the forward-looking statements. Risk factors that
could contribute to such differences include those matters more fully
disclosed in the Company's reports filed with the Securities and
Exchange Commission. The forward-looking information provided herein
represents the Company's estimates as of the date of the press
release, and subsequent events and developments may cause the
Company's estimates to change. The Company specifically disclaims any
obligation to update the forward-looking information in the future.
Therefore, this forward-looking information should not be relied upon
as representing the Company's estimates of its future financial
performance as of any date subsequent to the date of this press
release.
 
Investors: Sign Up for Email Alerts on Endonovo
 
 
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=3043430
 
 
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Senior Vice President of Investor Relations
(800) 701-1223, Ext. 108
Sbarnes@endonovo.com 
www.endonovo.com